GlassScriptPhysician profile
Azra S Ayubi
NPI 1316937030
$1,563.09
in general payments reported to CMS, 2019-2025
24 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $112 · 2021: $238 · 2022: $301 · 2023: $135 · 2024: $320 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $324.26 | 2019-2025 | Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $154.38 | 2019-2024 | Acessa Provu System, Novasure, Coolseal Generator |
| Astellas Pharma US INC | $122.87 | 2024-2025 | Veozah |
| Roche Diagnostics Corporation | $115.34 | 2019-2021 | |
| Pfizer INC. | $109.74 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $107.96 | 2021-2025 | |
| Daiichi Sankyo INC. | $100.30 | 2021-2024 | Injectafer |
| Coopersurgical, INC. | $90.30 | 2020-2024 | Paragard T 380a |
| Aspira Women'S Health INC | $76.16 | 2022-2024 | Ova1 |
| Myovant Sciences INC. | $44.21 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $42.05 | 2024-2025 | |
| Minerva Surgical, INC | $31.96 | 2025 | |
| Medtronic, INC. | $31.74 | 2022-2024 | Venaseal |
| Agile Therapeutics, INC. | $29.35 | 2024 | Twirla |
| Medtronic Vascular, INC. | $28.68 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $26.95 | 2021-2022 | |
| Ethicon US, LLC | $25.07 | 2024 | Ethicon, Stratafix |
| Becton, Dickinson and Company | $17.82 | 2023 | Bd Onclarity |
| Boston Scientific Corporation | $17.03 | 2019 | |
| Shield Therapeutics INC | $15.98 | 2023 | Accrufer |
| Davol INC. | $14.70 | 2022 | |
| Sumitomo Pharma America, INC. | $13.25 | 2024 | Myfembree |
| Meditrina | $11.69 | 2024 | |
| Organon LLC | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azra Ayubi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.